UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(State or Other | (Commission | (I.R.S. Employer | ||
Jurisdiction of | File Number) | Identification Number) | ||
Incorporation) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On June 29, 2020, United Therapeutics Corporation announced that it has entered into an amendment extending the term of its exclusive license agreement with Eli Lilly and Company (“Lilly”) covering the U.S. marketing, promotion, and sale of Adcirca® (tadalafil) tablets through December 31, 2023. Under the agreement, Lilly granted United Therapeutics an exclusive license for the right to develop, market, promote and commercialize Adcirca for the treatment of pulmonary hypertension in the United States. The agreement was previously set to expire on December 31, 2020. Other terms of the license agreement remain the same.
ADCIRCA is a registered trademark of Eli Lilly and Company.
Item 9.01. Exhibits
(d) Exhibits | ||
Exhibit No. | Description of Exhibit | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNITED THERAPEUTICS CORPORATION | ||
Dated: June 29, 2020 | By: | /s/ Paul A. Mahon |
Name: | Paul A. Mahon | |
Title: | General Counsel |
3